Eupraxia Pharmaceuticals, Inc. (EPRX)
7.50
+0.05
(+0.67%)
USD |
NASDAQ |
Sep 03, 16:00
7.50
0.00 (0.00%)
After-Hours: 20:00
Eupraxia Pharmaceuticals Shareholders Equity (Quarterly) : 131.28M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 131.28M |
| March 31, 2026 | 137.78M |
| December 31, 2025 | 82.04M |
| September 30, 2025 | 90.03M |
| June 30, 2025 | 22.55M |
| March 31, 2025 | 28.60M |
| December 31, 2024 | 33.40M |
| September 30, 2024 | 9.520M |
| June 30, 2024 | 14.83M |
| March 31, 2024 | 19.54M |
| December 31, 2023 | |
| September 30, 2023 | 12.61M |
| June 30, 2023 | 5.622M |
| March 31, 2023 | 6.379M |
| Date | Value |
|---|---|
| December 31, 2022 | 9.488M |
| September 30, 2022 | 14.78M |
| June 30, 2022 | 19.15M |
| March 31, 2022 | 13.79M |
| December 31, 2021 | 16.14M |
| September 30, 2021 | 18.64M |
| June 30, 2021 | 22.74M |
| March 31, 2021 | 20.03M |
| December 31, 2020 | -16.65M |
| September 30, 2020 | -16.01M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -13.64M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Edesa Biotech, Inc. | 8.811M |
| ProMIS Neurosciences, Inc. | 49.40M |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 139.91M |
| Total Liabilities (Quarterly) | 10.23M |
| Debt to Equity Ratio | 0.014 |
| Current Ratio | 16.00 |
| Net Debt Paydown Yield | -0.08% |